Accelerating Therapeutic Antibody Discovery: Innovative Technologies Transforming Hit Generation and Lead Characterization

Monoclonal antibody discovery has been a foundational innovation that continues to drive novel antibody therapeutics in research areas, including cancer, autoimmune disease, and infectious disease. As the demands and requirements for new antibodies continue to evolve, especially around safety, efficacy, and functional characterization, more powerful screening technologies are critical to antibody discovery and therapeutic development success. Unlike hybridoma and display technologies that can limit antibody diversity, have low campaign success, and require months to perform, the Beacon® optofluidic technology enables rapid selection of lead candidates by serial function-first screening of single B cells to increase success rates and shorten antibody discovery timelines to days.

In this presentation, Vincent Pai and Dr. Yu Liang will first highlight Bruker Cellular Analysis’ full Beacon antibody discovery suite for screening primary plasma cells and memory B cells, including the newest ability to discover antibody hits based on relative binding affinity, and share how customers can leverage optofluidic technology to rapidly discover high value monoclonal antibodies with the highest chances of success and fastest turnaround times.

They will then highlight how GenScript uses the Beacon optofluidic system for initial single B cell screening, followed by the state-of-the-art ProSpeed expression system for rapid re-expression and enabling world-class antibody characterization. Genscript’s ProSpeed™ single B cell screening service transforms lead characterization, including deep functional antibody profiling and enhanced B cell receptor sequence recovery, making it faster and more cost effective than traditional plasmid-based expression systems.

Live Webinar Information
Start Time:
October 31, 2024 11:00 AM Eastern
10:00 AM Central, 9:00 AM Mountain, 8:00 AM Pacific
Add to Calendar:
Estimated Length:
1 hour
Registration Time Remaining:
17 days, 18 hours
Register Now
In order to access this program after registering, a TAS account will be provided for you based on the information you have entered.

To access your account after your purchase, use the My Account links on the left hand side of this page to login using the information your provide here.
According to our records there is already a TAS account using the email address you have provided.

To continue with your registration please enter your account password. If you do not know your account password you can retrieve it here: Forgot Password?
First Name:
Last Name:
Email:
Confirm Email:
Organization:
Job Title:
Country:
The email address you have entered has an existing TAS account.

Please enter your password in the field below. Forgot Password?

Email:
Password:
Country:
Billing Address:
City:
State:
State/Province:
Zip:
Expiration: 
Accelerating Therapeutic Antibody Discovery: Innovative Technologies Transforming Hit Generation and Lead Characterization

Monoclonal antibody discovery has been a foundational innovation that continues to drive novel antibody therapeutics in research areas, including cancer, autoimmune disease, and infectious disease. As the demands and requirements for new antibodies continue to evolve, especially around safety, efficacy, and functional characterization, more powerful screening technologies are critical to antibody discovery and therapeutic development success. Unlike hybridoma and display technologies that can limit antibody diversity, have low campaign success, and require months to perform, the Beacon® optofluidic technology enables rapid selection of lead candidates by serial function-first screening of single B cells to increase success rates and shorten antibody discovery timelines to days.

In this presentation, Vincent Pai and Dr. Yu Liang will first highlight Bruker Cellular Analysis’ full Beacon antibody discovery suite for screening primary plasma cells and memory B cells, including the newest ability to discover antibody hits based on relative binding affinity, and share how customers can leverage optofluidic technology to rapidly discover high value monoclonal antibodies with the highest chances of success and fastest turnaround times.

They will then highlight how GenScript uses the Beacon optofluidic system for initial single B cell screening, followed by the state-of-the-art ProSpeed expression system for rapid re-expression and enabling world-class antibody characterization. Genscript’s ProSpeed™ single B cell screening service transforms lead characterization, including deep functional antibody profiling and enhanced B cell receptor sequence recovery, making it faster and more cost effective than traditional plasmid-based expression systems.

Speaker Information
Yu Liang  [ view bio ]
Vincent Pai  [ view bio ]
ProductAddPrice
Live Event + Archive
TAS Price:$0.00
Individual topic purchase: Selected